Global Cerebral Palsy Research
Report: By Type (Spastic Cerebral Palsy, Dyskinetic Cerebral Palsy, Hypotonic
Cerebral Palsy, Ataxic Cerebral Palsy, Other), by Diagnosis (Imaging Tests,
Others), by Treatment (Therapy, Medication, Other)– Forecast Till 2023
Market Scenario
Cerebral palsy (CP) is a group of
lifelong neurological disorders that affect movement and coordination, caused
by damage to or abnormalities inside the developing brain of the infant. CP can
occur before, during or soon after birth. Additionally, cerebral palsy can
develop from several factors such as lack of oxygen to the brain, genetic
conditions, brain infections, brain hemorrhage, chemical or substance abuse
during pregnancy, injury to the head, and severe jaundice.
The global cerebral
palsy market is driving owing to the growing prevalence of cerebral palsy
coupled with increasing awareness about the condition. Moreover, the growing
adoptions of medications for controlling the symptoms of the cerebral palsy are
anticipated to propel the market growth. Additionally, increasing expenditure
for the healthcare sector in developed economies and increasing insurance
coverage contribute to the growth of the market.
Despite the drivers, side effects
associated with medications and high treatment cost and lack of awareness in
some developing regions may hamper the market growth during the assessment
period.
Key players
Some of the prominent players in the
global cerebral palsy market are Allergen Plc, Cellular Biomedicine Group,
Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories,
Acorda Therapeutics, Inc., Medtronic, Meridigen Biotech Co., Ltd., GW
Pharmaceuticals Plc, and Cell Cure Neurosciences Ltd.
Segmentation
The global cerebral palsy market has been
segmented into type, diagnosis, and treatment.
The market, on the basis of type, has
been segmented into spastic cerebral palsy, dyskinetic cerebral palsy,
hypotonic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy.
The market, by diagnosis, has been
segmented into imaging tests and others. The imaging tests have been further
segmented into magnetic resonance imaging (MRI), cranial ultrasound, computed
tomography, and electroencephalogram.
The market, by treatment, has been
segmented into therapy, medication, surgery, and others. The therapy segment
has been segmented into nutrition therapy, hyperbaric oxygen therapy,
occupational therapy, physical therapy, stem cell therapy, and others. The
medication segment has been segmented into anti-convulsant drugs, muscle
relaxants, anti-depressant drugs, anti-inflammatory drugs, and others. Further,
the surgery segment has been segmented into orthopedic surgery and others.
Regional Summary
The Americas is expected to dominate the global
cerebral palsy market during the forecast period owing to the well-established
healthcare sector, growing awareness about CP, and the rising prevalence of
cerebral palsy in the region. The European market is expected to be the
second-largest market due to the growing healthcare expenditure and increasing
prevalence of cerebral palsy. Moreover, the market in Asia-Pacific is
anticipated to be the fastest-growing during the forecast period owing to the
developing healthcare infrastructure, and favorable government initiatives for
the healthcare sector. The Middle East & Africa is likely to account for
the least market share of the global cerebral palsy market owing to the lack of
economic development, especially in the African region.
Browse More Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report
No comments:
Post a Comment